Brightsurf Science News & Current Events

April 21, 2018
Correcting tiny differences in patient's position for radiotherapy could increase survival chances
Very small differences in the way a patient lies during radiotherapy treatment for lung or esophageal cancer can have an impact on how likely they are to survive, according to research presented at the ESTRO 37 conference.

New leads in the development and treatment of liver disease
A treatment gap remains for many conditions involving damage to the liver, the body's main organ for removing toxins, among other functions.

Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens
The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae and should be avoided when treating these organisms, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

New advances in the fight against cancer
Research into cancer can provide new insight into how this disease works and how it can be stopped.

Seven-day antibiotic course delivers similar outcomes to 14-days for Gram-negative bacteraemia
A seven-day course of antibiotic treatment for Gram-negative bacteraemia (GNB), a serious infection that occurs when bacteria get into the bloodstream, was shown to offer similar patient outcomes as a 14-day course, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

New hope for treating diabetic wounds that just won't heal
New research uncovers the role of a particular protein in maintaining diabetic wounds and suggests that reversing its effects could help aid wound healing in patients with diabetes.

Gene linked to fatal outcomes in P. aeruginosa BSI may be used as marker, target
Researchers discovered an easily measured gene linked to a high fatality rate, which could be used as a novel prognostic biomarker in patients with a Pseudomonas aeruginosa (P. aeruginosa) bloodstream infection, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

6-day antibiotic cellulitis therapy results in faster, greater relapse than 12-day course
Cellulitis treated with a six-day course of intravenous antibiotic flucloxacillin resulted in greater rates of relapse at 90 days post treatment despite having similar short-term results to that of the 12-day course, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.